Illumina has landed on a new leader after a monthslong proxy battle upended the DNA sequencing giant’s leadership earlier this year.

经过长达一个月的代理战斗，今年早些时候DNA测序巨头的领导层结束了，Illumina已经降落在一位新的领导者身上。

Jacob Thaysen, Ph.D., will make the jump after a decade at Agilent Technologies, where he served as president of its life sciences and applied markets group and helped lead its portfolios of diagnostics, analytical instruments, informatics services and cell analysis offerings. Thaysen is set to take the top job at Illumina starting Sept.

Jacob Thaysen博士将在安捷伦科技公司工作十年后跳出水面，在那里他担任生命科学和应用市场集团总裁，并帮助领导其诊断，分析仪器，信息服务和细胞分析产品组合。Thaysen将从9月开始在Illumina担任最高职位。

25..

25..

“I’m planning to hit the ground running and looking forward to working with the incredibly talented teams at Illumina,” Thaysen said in the company’s announcement.

Thaysen在该公司的公告中说：“我计划在地面上发挥作用，并期待与Illumina令人难以置信的人才团队合作。

Thaysen may have a marathon ahead of him: Illumina has been mired in legal battles on both sides of the Atlantic, with ongoing appeals against U.S and European antitrust regulators who sought to block the company’s multibillion-dollar acquisition of cancer blood test developer Grail.

Thaysen可能会在他面前进行马拉松比赛：Illumina在大西洋双方的法律斗争中陷入困境，目前正在呼吁美国和欧洲的反托拉斯监管机构试图阻止该公司数十亿美元收购癌症血液检测开发商Grail。

At the same time, the company recently shrank its financial projections for the remainder of the year. After forecasting annual growth between 7% and 10% following this year’s first quarter, the company said last month that it now expects revenues from DNA sequencers and supplies to remain “approximately flat” despite the recent launch and growing placements of its latest NovaSeq X hardware, which touts the ability to read full human genomes at a cost of about $200..

与此同时，该公司最近缩减了今年剩余时间的财务预测。在今年第一季度之后预测年增长率将在7%至10%之间之后，该公司上个月表示，尽管最近推出了最新的NovaSeq X硬件并不断增加，但现在预计DNA测序仪和供应的收入将保持“大致平稳”。这吹捧着以约200美元的成本读取完整人类基因组的能力。。

This past June also saw Illumina begin a slate of layoffs as part of a plan to shave off at least $100 million from its 2023 expenses.

去年6月，Illumina公司也开始了一系列停工计划，作为计划从2023年支出中至少削减1亿美元的一部分。

The company’s August 2021 decision to move forward with its deal for Grail without first receiving government approvals has also brought down record fines from the EU—totaling nearly a half-billion dollars—and ultimately set the stage for activist investor Carl Icahn to lead a revolt against the company, further sparked by declines in Illumina’s stock value..

该公司于2021年8月决定在未经政府批准的情况下推进Grail交易，也降低了欧盟总计近50亿美元的创纪录罚款，最终为活动家投资者卡尔·伊坎（Carl Icahn）引发反对该公司，进一步由Illumina股票价值下降引发。。

After a public war of words this past spring, Illumina shareholders voted to replace the company’s board chair, John Thompson, with Icahn-endorsed nominee Andrew Teno. Illumina’s previous CEO, longtime chief Francis deSouza, stepped down shortly thereafter in June.

在去年春天的一场公开战争之后，Illumina股东投票将公司董事会主席John Thompson替换为Icahn认可的提名人Andrew Teno。Illumina之前的首席执行官，长期担任首席执行官Francis deSouza，此后不久于6月辞职。

Most recently, the U.S. Securities and Exchange Commission (SEC) launched its own probe into Illumina’s quest for Grail—which the company has held at arm’s length, with separate management, for the past two years. The SEC has requested documents “related to the conduct and compensation” of leaders at both companies, according to Illumina..

最近，美国证券交易委员会（SEC）推出了自己的调查，调查Illumina在过去两年中一直坚持独立管理的公司对Grail的追求。根据Illumina的说法，美国证券交易委员会已要求两家公司领导者提供“与行为和赔偿有关”的文件。。

Going forward, Illumina will be banking on Thaysen’s history in genomics and tech.

展望未来，Illumina将致力于Thaysen在基因组学和技术领域的历史。

He previously led Agilent life sciences franchises that brought in a total of $4 billion in 2022 revenue, while counting more than 50,000 customers, according to Illumina. Before that, Thaysen served as president of Agilent’s diagnostics and genomics group from 2014 to 2018, during his 10-year tenure with the company..

据Illumina公司称，他之前领导安捷伦生命科学特许经营，在2022年共带来40亿美元的收入，同时也有超过5万客户。在此之前，Thaysen在公司任职10年期间，于2014年至2018年担任安捷伦诊断与基因组学集团总裁。。

“Jacob’s unique combination of deep technological and commercial experience will be a great addition to Illumina,” said Stephen MacMillan, CEO of Hologic and chair of Illumina’s board. “He brings a fresh perspective, a demonstrated track record driving profitable growth and a strong commitment to create value for all of Illumina’s stakeholders.”.

Hologic首席执行官兼Illumina董事会主席斯蒂芬·麦克米伦（Stephen MacMillan）说：“雅各布独特的深度技术和商业经验相结合将成为Illumina的一大补充。“他带来了新的视角，展示了良好的业绩，推动了有利可图的增长，并坚定承诺为所有Illumina的利益相关者创造价值。”。

Charles Dadswell, who has served as Illumina’s interim CEO since deSouza’s departure, will resume his position as general counsel once Thaysen takes the helm.

Charles Dadswell自deSouza离开以来一直担任Illumina的临时首席执行官，一旦Thaysen接手，他将恢复担任总顾问的职位。